Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease

Completed · Phase 3 · Has a placebo group

Conditions studied: Fabry Disease

In brief

This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.

Key facts

Study ID
NCT03425539
Run by
Idorsia Pharmaceuticals Ltd.
People needed
118
Starts
2018-06-21
Expected to finish
2021-09-02
Last updated by the study team
2024-08-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.